Royalty Pharma (RPRX) Projected to Post Quarterly Earnings on Tuesday

Royalty Pharma (NASDAQ:RPRX) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 11th. Analysts expect Royalty Pharma to post earnings of $0.99 per share and revenue of $743.60 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $31.33 on Tuesday. Royalty Pharma has a one year low of $24.05 and a one year high of $32.21. The firm has a market cap of $18.46 billion, a PE ratio of 16.23 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The stock’s fifty day moving average price is $27.34 and its two-hundred day moving average price is $27.53.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.81%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. Royalty Pharma’s dividend payout ratio is currently 43.52%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RPRX. Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Royalty Pharma currently has an average rating of “Buy” and an average target price of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.